With the availability of new therapies like Sotorasib, which targets KRAS G12C mutations in NSCLC, identifying factors that help pinpoint patients more likely to harbour these mutations is crucial [36, 56]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.